Home/Filings/4/0001209191-23-013263
4//SEC Filing

Kwan Rudolf 4

Accession 0001209191-23-013263

CIK 0001300699other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 5:07 PM ET

Size

22.3 KB

Accession

0001209191-23-013263

Insider Transaction Report

Form 4
Period: 2023-02-24
Kwan Rudolf
EVP, Chief Medical Officer
Transactions
  • Award

    Common Stock

    2023-02-24$2.74/sh+1,788$4,89932,390 total
Holdings
  • Stock Option (Right to Buy)

    Exercise: $91.00From: 2018-02-12Exp: 2024-02-12Common Stock (6,000 underlying)
    6,000
  • Stock Option (Right to Buy)

    Exercise: $91.00From: 2017-06-12Exp: 2024-06-12Common Stock (2,400 underlying)
    2,400
  • Stock Option (Right to Buy)

    Exercise: $110.00From: 2018-12-16Exp: 2024-12-16Common Stock (10,000 underlying)
    10,000
  • Stock Option (Right to Buy)

    Exercise: $150.00From: 2019-05-22Exp: 2025-05-22Common Stock (6,000 underlying)
    6,000
  • Stock Option (Right to Buy)

    Exercise: $220.00From: 2020-06-13Exp: 2027-06-13Common Stock (7,000 underlying)
    7,000
  • Stock Option (Right to Buy)

    Exercise: $346.00From: 2022-03-27Exp: 2028-03-27Common Stock (6,000 underlying)
    6,000
  • Stock Option (Right to Buy)

    Exercise: $91.00From: 2018-05-13Exp: 2023-05-13Common Stock (2,400 underlying)
    2,400
  • Stock Option (Right to Buy)

    Exercise: $263.40Exp: 2029-02-28Common Stock (6,000 underlying)
    6,000
  • Stock Option (Right to Buy)

    Exercise: $249.00Exp: 2030-06-05Common Stock (7,000 underlying)
    7,000
  • Stock Option (Right to Buy)

    Exercise: $76.00Exp: 2031-08-03Common Stock (3,500 underlying)
    3,500
  • Restricted Stock Units

    Common Stock (2,625 underlying)
    2,625
  • Stock Option (Right to Buy)

    Exercise: $13.31Exp: 2032-07-20Common Stock (3,750 underlying)
    3,750
Footnotes (10)
  • [F1]Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
  • [F10]This option vests in four equal annual installments beginning on July 20, 2023.
  • [F2]As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock.
  • [F3]This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023.
  • [F4]This option vests in four equal annual installments beginning on February 28, 2020.
  • [F5]This option vests in four equal annual installments beginning on June 5, 2021.
  • [F6]The option vests in four equal annual installments beginning on August 3, 2022.
  • [F7]Each restricted stock unit represents a contingent right to receive one share of stock.
  • [F8]The restricted stock units vest in four equal annual installments beginning on August 3, 2022.
  • [F9]The restricted stock units were adjusted to reflect the reverse stock split that occurred on February 15, 2023.

Issuer

Athenex, Inc.

CIK 0001300699

Entity typeother

Related Parties

1
  • filerCIK 0001708965

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 5:07 PM ET
Size
22.3 KB